Results may impact clinical management of cancers treated with the alkylating agent cyclophosphamide, based on its effects on the differentiation of pro-inflammatory Th17 cells.
Introduction
Cyclophosphamide (CTX) at 100-150 mg/kg in mice is known for decades to suppress inhibitory T cell subsets promoting delayed type hypersensitivity responses (DTH), IFNγ-mediated antitumor T cell immunity synergizing with anti-cancer vaccines, TLR agonists or adoptive T cell transfer (1, 2). The CTX-induced IFNα production might account for the augmented antibody responses and the persistence of memory T cells (3) . Interestingly, CTX can also ablate a subset of dendritic cells involved in peripheral tolerance, thereby contributing to enhanced Th1 responses and antitumor effects (4) . Pioneering pilot studies indicated that CTX alone or combined with vaccines could restore NK and TCR-driven effector functions in end stage cancer patients (5) , augment DTH responses (6) , decrease the proportions of Tregs (5) and prolong survival of metastatic cancer patients (7) .
Recent preclinical studies indicated a close association between IL-17 produced by tumor infiltrating lymphocytes and tumor destruction (8, 9, 10) . IL-17A-deficient mice exhibited accelerated tumor progression correlating with decreased NK and tumor specific T cell IFNγ release (8) or enhanced establishment of lung metastases in a melanoma model (10) . The adoptively transferred antigen-specific Th17 CD4 + T cells evolved into IFNγ-producing Th1-like lymphocytes capable of eliminating large tumor burdens (9) or behave as helper cells generating potent CTL responses (10) .
Given the plasticity of Th17 cells (11) and the unstable phenotype of inducible Tregs (12), we addressed whether CTX could exert significant effects on these in transit-lymphocytes subsets. We found that at a low or lymphodepleting dosage in mice and metronomic in humans, CTX promoted the differentiation of Th17 cells in cancer patients that could be recovered in blood and tumor ascitis. Animal models suggested that CTX-induced Th17 differentiation did not result from the conversion of Tregs.
with anti-CD3α mAb (0.5 µg/well, eBioscience) and/or anti-CD28 mAb (2 µg/ml, BD Pharmingen) and/or rIL-1β and rIL-23 (10 ng/ml, R&D Systems MoFlo-mediated sorting from PBMCs or ascitis fluids and incubated at a ratio of 10 cells for 1
anti-CD3/anti-CD28 microbead (with 10 IU of rIL-2/ml) The supernatants were assayed at day 3
by ELISA for human IL-17 (R&D Systems) or IFNγ (BD OptEIA™).
Results and Discussion
At 100 mg/kg, CTX blocked the growth kinetics of subcutaneous B16F10 (not shown) in a T celldependent manner (1, 2). We examined more closely the phenotype of T cells during CTX therapy. A single injection of 100 mg/kg of CTX resulted, by 7 days, in a 50% reduction of the spleen cellularity including B, CD4 + T and CD8 + T cells (Fig. 1A ) but no significant modulations of the proportions of the CD4 + , CD8 + and γδ T cell subsets (not shown). Seven days post-CTX, the TCR-driven cytokine release was markedly increased in melanoma bearing mice (Fig. 1B) in spleens (but not in draining lymph nodes, not shown). While IFNγ production was increased both in CD4 + and CD8 + T cells by CTX (Suppl. Fig. 2 ), CTX-driven IL-17 release rose specifically in CD4 + T cells (Fig. 1C) . In similar conditions, CTX did not significantly induce IL-17 production by CD8 + (Fig. 1C) (Fig. 2) . Therefore, the major source of IL-17 at day 7 post-injection of CTX in spleens is the CD4 + T cell pool.
To further elucidate whether metronomic dosage of the alkylating agent CTX may also convert CD4 + T cells into Th17 producers in humans, we analyzed the secretory pattern of T lymphocytes prior to and after a 21 day therapy with 50 mg/day of oral CTX in a cohort of 21 advanced cancer patients (Table 1 ). This metronomic dosage in cancer patients promoted a drop in B cell counts (but no significant decrease of T cell absolute numbers, CTX dose effect. Id. As in B. but using increasing dosages of intraperitoneal CTX. Experiments were carried out on 3 to 7 independent mice spleens. B, C, D show IL-17 and/or IFNγ  secretion levels in 48 hrs supernatants monitored using commercial ELISA kits. Graphs from A and B depict the data of 2 or 3 pooled experiments and each plot corresponds to one mouse. Statistical analyses using Mann Whitney test indicated significant differences at 95% confidence interval.
Means and SEM are shown.* p<0.05, ** p<0.01, *** p<0.001 and ns: "non significant". 
